MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Mereo BioPharma to contact them to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Mereo [2][7]. Group 2: Clinical Trial Results - Mereo announced that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the failure to meet primary endpoints, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price fell by $2.02 per share, or 87.64%, closing at $0.28 per share on December 29, 2025 [6].